$MAJI in October the company was awareded Orphan Drug Designation for its exosome-based GBM treatment also known as Glioblastoma multiforme. Only 11% of orphan drug designations are awarded at the preclinical stage. "Our breakthrough exosomal technology has the ability to deliver a wide range of therapeutics, including genetic material, into cells afflicted with cancer, such as GBM. The therapeutic technology presented in this orphan drug application is a method for using exosomes loaded with desired nucleic acids, in the effective treatment of GBM when combined with currently available standard anticancer therapy." They plan to work with investment bankers to expand and monetize the therapy. A product like this could bring in 10's of millions of dollars alone to the company. otcmarkets.com/stock/MAJI/new…
